ANI Pharmaceuticals

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for ANI's rapidly expanding research and development program. With several ANDAs pending FDA approval, and in various stages of development, ANI is poised for tremendous growth in the months and years to come!
Baudette, US
Size (employees)
143 (est)+33%
ANI Pharmaceuticals is headquartered in Baudette, US

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has an office in Baudette
Baudette, US (HQ)
210 Main St W
Baudette, US
455 Idc Rd Sw

ANI Pharmaceuticals Data and Metrics

ANI Pharmaceuticals Financial Metrics

ANI Pharmaceuticals's revenue was reported to be $128.6 m in FY, 2016 which is a 69% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

128.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

79.8 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

3.9 m

EBIT (FY, 2016)

20.1 m

Market capitalization (26-May-2017)

535 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

27.4 m
ANI Pharmaceuticals's current market capitalization is $535 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


30.1 m56 m76.3 m128.6 m

Revenue growth, %


Cost of goods sold

10 m11.5 m12.7 m48.8 m

Gross profit

20.1 m44.5 m63.6 m79.8 m

Gross profit Margin, %


Operating expense total

19.2 m24.5 m30.9 m108.5 m


898 k20 m32.7 m20.1 m

EBIT margin, %


Interest expense

467 k787 k11 m11.3 m

Net Income

301 k28.7 m15.4 m3.9 m
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


11.1 m169 m154.7 m27.4 m

Accounts Receivable

12.5 m17.3 m21.9 m45.9 m


580 k1.1 m1.5 m3.6 m

Current Assets

27.7 m203.5 m192.6 m103 m


4.5 m5.2 m7.1 m11 m


1.8 m1.8 m1.8 m1.8 m

Total Assets

44.5 m263.7 m285.3 m322.9 m

Accounts Payable

1.4 m2.7 m2.1 m3.4 m

Current Liabilities

3.5 m13.2 m11.8 m31.9 m

Additional Paid-in Capital

89.5 m159.5 m164.4 m172.6 m

Retained Earnings

(48.5 m)(19.7 m)(4.4 m)(2.9 m)

Total Equity

41 m139.8 m160.1 m169.6 m

Financial Leverage

1.1 x1.9 x1.8 x1.9 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

301 k28.7 m15.4 m3.9 m

Depreciation and Amortization

1.1 m3.9 m6.9 m22.3 m

Accounts Receivable

(7.1 m)(4.8 m)(4.6 m)(24 m)


(708 k)(3.5 m)(314 k)(647 k)

Accounts Payable

(565 k)225 k(1 m)1.1 m

Cash From Operating Activities

11.1 m157.9 m(14.4 m)27.5 m

Purchases of PP&E

(191 k)(1.1 m)(2.2 m)(4.6 m)

Cash From Investing Activities

20.3 m(35.8 m)(32.7 m)(154.1 m)

Interest Paid

250 k4.2 m

Income Taxes Paid

147 k13.3 m9.5 m
Y, 2016

Financial Leverage

1.9 x

ANI Pharmaceuticals Market Value History

ANI Pharmaceuticals Company Life and Culture

You may also be interested in